WILMINGTON, Del. and ASHDOD, Israel, May 23, 2017
/PRNewswire/ -- Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring
glucose levels of people with type 2 diabetes and prediabetes, today announced that the results of a study evaluating the
influence of medications on the accuracy of GlucoTrack® will be presented at the American Diabetes Association's (ADA)
77th Scientific Sessions, June 9-13, 2017, in San Diego,
CA.
The presentation details are as follows:
|
Poster Title:
|
Influence of Medications on the Accuracy of GlucoTrack® - A Non-invasive
Glucose Monitoring Device
|
|
Abstract
#:
|
937
|
|
Room:
|
Hall B
|
|
Date:
|
Saturday, June 10, 2017
|
|
Time:
|
11:30AM – 12:30PM
|
|
Presenter:
|
Amit Rozner, Senior Research Engineer at Integrity Applications
|
For more information, please visit the company website at www.integrity-app.com.
About GlucoTrack®
GlucoTrack® is a truly non-invasive monitoring device that rapidly measures and displays an individual's glucose level
without finger pricking or any pain.
GlucoTrack® features a small sensor that clips to the earlobe and measures the user's glucose level using innovative and
patented sensor technology. The measured signals are analyzed using a proprietary algorithm and then a calculated glucose level
is displayed on a small handheld device the size of a small mobile phone. The derived glucose measurements are stored in the
device and calculates a projected HbA1c level using a validated algorithm. The device also displays the glucose values
graphically allowing the user to monitor glucose over a period of time.
GlucoTrack® has received CE Mark and KFDA approvals for type 2 diabetes and prediabetics, and is currently in the early stages
of commercialization in Europe, South Korea and other
geographies.
GlucoTrack® is expected to begin clinical trials for United States FDA approval in late 2017. The product is currently
experimental in the United States and is limited to investigational use only.
About Integrity Applications, Inc.
Integrity Applications was founded in 2001 and is focused on the design, development and commercialization of
non-invasive glucose monitoring technologies for patients with diabetes and pre-diabetes. The company has developed GlucoTrack®,
a proprietary noninvasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the
pain, incremental cost, difficulty or discomfort of conventional invasive finger stick devices. Integrity Applications Inc. is a
Delaware corporation, with headquarters in the United States
and an R&D site in Ashdod, Israel. For more information, please visit www.integrity-app.com and www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the generality of the foregoing, words such as "expect", "plan" and "will" are
intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity
Applications' actual results and could cause such results to differ materially from any forward-looking statements that may be
made in this news release. Factors that may affect Integrity Applications' results include, but are not limited to, the ability
of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity
offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory
approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks
relating to its current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel,
including sales and distribution personnel; and the additional risk factors described in Integrity Applications' filings with the
U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the SEC on March 30, 2017.
MEDIA CONTACTS
Erich Sandoval / Amy Wheeler
Lazar Partners Ltd.
esandoval@lazarpartners.com / awheeler@lazarpartners.com
+1 (917) 497-2867 / +1 (646) 871-8486
INVESTOR CONTACTS
Matthew Ventimiglia
Lazar Partners Ltd.
mventimiglia@lazarpartners.com
+1 (212) 599-1265
Sami Sassoun, CFO Integrity Applications
SamiS@integrity-app.com
+972 (8) 675-7878 Ext. 400
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/integrity-applications-to-present-glucotrack-data-at-american-diabetes-associations-77th-scientific-sessions-300462076.html
SOURCE Integrity Applications, Inc.